

**Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb)**  
**Recombinant Antibody**  
**Catalog # APR10131**

**Specification**

**Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">Q13433</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.96 KDa

**Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb) - Additional Information**

**Target/Specificity**  
LIV-1 / SLC39A6

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb) - Protein Information**

**Name** SLC39A6 ([HGNC:18607](#))

**Synonyms** LIV1, ZIP6

**Function**

Zinc-influx transporter which plays a role in zinc homeostasis and in the induction of epithelial-to-mesenchymal transition (EMT) (PubMed:<a href="http://www.uniprot.org/citations/12839489" target="\_blank">12839489</a>, PubMed:<a href="http://www.uniprot.org/citations/18272141" target="\_blank">18272141</a>, PubMed:<a href="http://www.uniprot.org/citations/21422171" target="\_blank">21422171</a>, PubMed:<a href="http://www.uniprot.org/citations/23919497" target="\_blank">23919497</a>, PubMed:<a href="http://www.uniprot.org/citations/27274087" target="\_blank">27274087</a>, PubMed:<a href="http://www.uniprot.org/citations/34394081" target="\_blank">34394081</a>). When associated with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates cellular zinc uptake to trigger cells to undergo epithelial- to- mesenchymal transition (EMT) (PubMed:<a href="http://www.uniprot.org/citations/21422171" target="\_blank">21422171</a>, PubMed:<a href="http://www.uniprot.org/citations/34394081" target="\_blank">34394081</a>).

href="http://www.uniprot.org/citations/27274087" target="\_blank">27274087

The SLC39A10-SLC39A6 heterodimer also controls NCAM1 phosphorylation and its integration into focal adhesion complexes during EMT (By similarity). Zinc influx inactivates GSK3B, enabling unphosphorylated SNAI1 in the nucleus to down-regulate adherence genes such as CDH1, causing loss of cell adherence (PubMed:<a href="http://www.uniprot.org/citations/23919497" target="\_blank">23919497). In addition, the SLC39A10-SLC39A6 heterodimer plays an essential role in initiating mitosis by importing zinc into cells to initiate a pathway resulting in the onset of mitosis (PubMed:<a href="http://www.uniprot.org/citations/32797246" target="\_blank">32797246). Participates in the T-cell receptor signaling regulation by mediating cellular zinc uptake into activated lymphocytes (PubMed:<a href="http://www.uniprot.org/citations/21422171" target="\_blank">21422171, PubMed:<a href="http://www.uniprot.org/citations/30552163" target="\_blank">30552163, PubMed:<a href="http://www.uniprot.org/citations/34394081" target="\_blank">34394081). Regulates the zinc influx necessary for proper meiotic progression to metaphase II (MII) that allows the oocyte-to-egg transition (PubMed:<a href="http://www.uniprot.org/citations/25143461" target="\_blank">25143461).

### Cellular Location

Cell membrane; Multi-pass membrane protein. Cell projection, lamellipodium membrane; Multi-pass membrane protein. Membrane raft; Multi-pass membrane protein. Apical cell membrane {ECO:0000250|UniProtKB:Q4V887} Note=Localizes to lipid rafts in T cells and is recruited into the immunological synapse in response to TCR stimulation (PubMed:34394081) In the choroid plexus is limited to the apical membrane in epithelial cells (By similarity). {ECO:0000250|UniProtKB:Q4V887, ECO:0000269|PubMed:34394081}

### Tissue Location


Highly expressed in the breast, prostate, placenta, kidney, pituitary and corpus callosum (PubMed:12839489). Weakly expressed in heart and intestine. Also highly expressed in cells derived from an adenocarcinoma of the cervix and lung carcinoma (PubMed:12839489).


### Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-LIV-1 / SLC39A6 Reference Antibody (IadiratuzumAb) - Images






Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) is more than 98.2%, determined by SEC-HPLC.



Immobilized human LIV 1 His at 2 μg/mL can bind Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) EC<sub>50</sub>=0.005145 μg/mL